Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chlorazolamide (5-(2-chlorophenyl)-1,3,4-thiadiazole-2-sulfonamide) is a potent sulfonamide-based inhibitor of carbonic anhydrase (CA) isozymes, specifically CA I, II, and IV. These enzymes play a critical role in the secretion of aqueous humor in the eye. Although the parent sulfonamide exhibits poor topical efficacy in lowering intraocular pressure (IOP) when administered as a suspension, its metal complexes—including derivatives of magnesium, zinc, manganese, and copper—have shown significant IOP-lowering effects in animal models. The drug's mechanism involves the near-total inhibition of CA II in ocular tissues, which reduces fluid production and makes it a candidate for the treatment of glaucoma and ocular hypertension.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chlorazolamide.